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Abstract
Background: Candida-associated denture stomatitis is a frequent infectious disease. Treatment of this oral
condition is difficult because failures and recurrences are common. The aim of this study was to test the in vitro
antifungal activity of pure constituents of essentials oils.
Methods: Eight terpenic derivatives (carvacrol, farnesol, geraniol, linalool, menthol, menthone, terpinen-4-ol, and a-
terpineol), a phenylpropanoid (eugenol), a phenethyl alcohol (tyrosol) and fluconazole were evaluated against 38
Candida isolated from denture-wearers and 10 collection Candida strains by the CLSI M27-A3 broth microdilution
method.
Results: Almost all the tested compounds showed antifungal activity with MIC ranges of 0.03-0.25% for eugenol
and linalool, 0.03-0.12% for geraniol, 0.06-0.5% for menthol, a-terpineol and terpinen-4-ol, 0.03-0.5% for carvacrol,
and 0.06-4% for menthone. These compounds, with the exception of farnesol, menthone and tyrosol, showed
important in vitro activities against the fluconazole-resistant and susceptible-dose dependent Candida isolates.
Conclusions: Carvacrol, eugenol, geraniol, linalool and terpinen-4-ol were very active in vitro against oral Candida
isolates. Their fungistatic and fungicidal activities might convert them into promising alternatives for the topic
treatment of oral candidiasis and denture stomatitis.
Background
Denture stomatitis is a common inflammatory reaction
in denture-wearing patients, characterized by an erythe-
matous inflammation of mucosal areas covered by den-
tures. Although this clinical entity is multifactorial,
Candida albicans is the major etiological agent [1].
Moreover, other species of Candida,s u c ha sC. glab-
rata, C. tropicalis, C. krusei, C. parapsilosis and C.
dubliniensis have been isolated from patients with den-
ture stomatitis [2-4]. Different treatments have been
proposed for Candida-associated denture stomatitis.
However, there is a low number of antifungal agents
and therapy can induce side effects, resistance and/or
recurrence [1,5]. Thus, new therapeutic strategies are
necessary and natural products can play an important
role in the treatment as some of them can be included
in mouthrinses or tooth pastes. Among natural pro-
ducts, essential oils are promising therapeutic tools for
oral infections. These oils are complex mixtures of vola-
tile compounds obtained from plants, such as the terpe-
noids, with antioxidant and antimicrobial properties
against a wide range of pathogens, including Candida
albicans and dermatophytes [6-9].
The aim of the current study was to investigate the in
vitro activity of eight terpenic derivatives (carvacrol, far-
nesol, geraniol, linalool, menthol, menthone, terpinen-4-
ol, and a-terpineol), a phenylpropanoid (eugenol) and a
phenethyl alcohol (tyrosol) against oral Candida isolates
from patients suffering from denture stomatitis.
Methods
Microorganisms
A total of 38 oral isolates were tested, including 10 C.
albicans,1 0C. glabrata,1 0C. tropicalis,5C. guillier-
mondii, and 1 isolate each of C. parapsilosis, C. dubli-
niensis and C. krusei. The clinical isolates were
randomly selected from those recovered from a prospec-
tive study in denture wearers attending the Odontology
clinics at the Universidad del País Vasco/Euskal Herriko
Unibertsitatea, Bilbao (Spain). Demographic and clinical
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elsewhere [2]. The institutional review board of Univer-
sidad del País Vasco/Euskal Herriko Unibertsitatea
approved the study and informed consent was obtained
in each patient included in the study. There were also
studied 10 type strains from the American Type Culture
Collection (ATCC) and the National Collection of
Pathogenic Fungi (NCPF) including C. albicans ATCC
90028, C. albicans NCPF 3153, C. glabrata ATCC
90030, C. glabrata NCPF 3203, C. dubliniensis NCPF
3949, C. guilliermondii NCPF 3099, C. krusei ATCC
6258, C. parapsilosis ATCC 22019, C. tropicalis NCPF
3111, and the C. albicans NCPF 3153 hypha-defective
mutant Ca2 (kindly donated by Professor Antonio Cas-
sone, Istituto Superiore di Sanità, Rome, Italy). Isolates
were identified by conventional mycological methods,
such as the germ tube test in serum, microscopic mor-
phology, chlamydoconidia production in corn meal agar
with Tween 80, and carbon source assimilation with the
commercial kit ID 32 C (bioMérieux, France) [10].
Terpenes
All evaluated compounds were purchased from Sigma
(Sigma-Aldrich, USA) and included: carvacrol (5-isopro-
pyl-2-methylphenol) from Satureja hortensis,e u g e n o l
(4-allyl-2-methoxyphenol) from Pimenta dioica, farnesol
((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol) from
Vachellia farnesiana, geraniol (3,7-dimethylocta-2,6-
dien-1-ol) from Rosa damascena, linalool (3,7-dimethy-
locta-1,6-dien-3-ol) from Coriandrum sativum,m e n t h o l
((1R,2S,5R)-2-isopropyl-5-methylcyclohexanol) from
Mentha piperita, menthone ((2S,5R)-trans-2-isopropyl-
5-methylcyclohexanone) from Mentha piperita,t e r p i -
nen-4-ol (4-isopropyl-1-methyl-1-cyclohexen-4-ol) from
Melaleuca alternifolia, a-terpineol (2-(4-methyl-1-cyclo-
hex-3-enyl) propan-2-ol) from Artemisia annua,a n d
tyrosol (4-(2-hydroxyethyl)phenol) from Olea europaea
(Figure 1). The compounds were prepared as stock solu-
tion of 16% (volume/volume -v/v-) in RPMI 1640 med-
ium and 0.1% (v/v) Tween 80 (Sigma-Aldrich) [11].
In vitro antifungal activity testing
The antifungal activities of terpenes and fluconazole (as
a positive control) were determined by broth microdilu-
tion method using two fold serial dilutions in RPMI
1640 medium, as described in the document M27-A3
from the Clinical Laboratory Standards Institute (CLSI)
for yeasts [12]. Briefly, chemical compounds were dis-
solved in RPMI 1640 medium buffered to pH 7.0 with
0.165 M morpholinepropanesulfonic acid. After shaking,
100 μl aliquots were added to the wells of 96-well
microtiter plates with final concentrations ranging from
0.01% to 8% (v/v). To enhance the compounds solubi-
lity, Tween 80 was included in all assays at a final
concentration of 0.05% (v/v) [11]. Fluconazole was pre-
pared in pure water. Reference microdilution trays con-
taining serial twofold dilutions of this drug were
prepared in RPMI 1640 medium buffered to pH 7.0
with 0.165 M morpholinepropanesulfonic acid (MOPS)
buffer in 96-well plates, and stored at -70°C for no
longer than 3 months.
Yeast inocula were prepared by growing the isolates
on Sabouraud dextrose agar plates for 24 h at 37°C and
adjusting to a final concentration between 1 × 10
3 and 5
×1 0
3 cells/ml in sterile saline. A 100 μls u s p e n s i o no f
each of the Candida strains was added to individual
wells and cultivated at 37°C for 24-48 h. Fluconazole
concentrations, when reconstituted with the yeast sus-
p e n s i o n s ,r a n g e df r o m0 . 1 2t o6 4μg/ml. Chemical-free
and yeast-free controls were included.
Determination of minimum inhibitory and minimum
fungicidal concentrations
The minimum inhibitory concentration (MIC) of the
evaluated compounds for each isolate was determined
according to the CLSI M27-A3 methodology. The MIC
was defined as the lowest concentration that produced a
prominent decrease of fungal growth (inhibition ≥ 50%)
compared with growth control. The minimum concen-
tration of drug that inhibited 90% and 50% of the isolates
tested was defined as MIC90 and MIC50, respectively.
The MIC of fluconazole was read as the lowest con-
centration that produced a prominent decrease of
growth (MIC2: inhibition ≥ 50%) relative to the control
of growth, with no antifungal agent. Classification of iso-
lates in terms of their susceptibilities to these antifungal
agents was based on the MIC breakpoints recommended
in the M27-A3 protocol and the M27-S3 supplement of






Figure 1 Formulae of the eight terpenic derivates (carvacrol,
farnesol, geraniol, linalool, menthol, menthone, terpinen-4-ol,
and a-terpineol), the phenylpropanoid (eugenol) and the
phenethyl alcohol (tyrosol) studied.
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32 μg/ml, and the MIC for resistance was ≥ 64 μg/ml.
For quality control, C. krusei ATCC 6258, and C. para-
psilosis ATCC 22019, were used.
Minimum fungicidal concentration (MFC) determina-
tions were performed according to the modifications
suggested by Cantón et al. [13]. Fungicidal activity was
defined as a ≥ 99.9% reduction in the number of col-
ony-forming units from the starting inoculum count,
whilst fungistatic activity was defined as ≤ 99.9% reduc-
tion. The minimum concentration of drug that is fungi-
cidal to 90% of the isolates was defined as MFC90.
Statistical analysis
Unless otherwise specified, all tests were performed in
triplicate in separate experiments. Descriptive statistics
were used for MIC, MFC, the range and the geometric
mean of these parameters. In vitro susceptibility testing
data from 24 h and 48 h were compared for all natural
compounds with the aim of detecting differences
between both reading times. Comparisons between
group values were performed by Student’s t-test, being p
< 0.05 regarded as statistically significant.
Results
The MIC and MFC values of the 10 tested compounds
against the 10 type strains studied at 24 h are summar-
ized in Table 1. Table 2 shows MIC values of these com-
pounds against oral isolates. The results confirmed the
antifungal activity of almost all the tested compounds.
The range of MICs at 24 h was 0.03-0.5% for carvacrol,
0.03-0.25% for the phenylpropanoid eugenol, 0.03-0.12%
for geraniol, 0.03-0.25% for linalool, 0.06-0.5% for
menthol, 0.06-4% for menthone, 0.06-0.5% for terpinen-
4-ol, 0.06-0.5% for a-terpineol, and 0.25-32 μg/ml for flu-
conazole. Tween 80 at 0.05% (v/v) did not show antifun-
gal activity against the microorganisms studied (data not
shown). Moreover, MIC readings at 48 h did not differ
markedly from readings at 24 h (p values were between
0.06 and 0.67). There were no differences over a dilution
between the three measurements for each test, but the
highest MIC was considered for calculations.
The most actives compounds against C. albicans were
eugenol, geraniol, linalool and terpinen-4-ol with MIC50
= 0.12%. The MIC50 of geraniol for C. tropicalis was
0.03% and for C. glabrata and C. guillermondii was
0.06%. Eugenol and linalool were also very active against
C. glabrata, C. guillermondii and C. tropicalis with
MIC50 =0 . 0 6 % .F u r t h e r m o r e ,t erpinen-4-ol was also
active against C. tropicalis with (MIC50 = 0.06%), and C.
glabrata and C. guillermondii (MIC50 = 0.12% for both
species). In addition, carvacrol was also effective against
C. glabrata and C. tropicalis (MIC50 =0 . 1 2 %f o rb o t h
species) and menthol against C. glabrata, C. guillermon-
dii and C. tropicalis with MIC50 = 0.12%. The MIC50 of
menthone for C. tropicalis was 0.06% and for C. glab-
rata was 0.12%. These compounds were active against
those species such as C. glabrata and C. krusei including
isolates categorized as susceptible-dose dependent (2 or
5o u to f1 0C. glabrata at 24 or 48 h, respectively) and
resistant (1 C. krusei) to fluconazole.
Farnesol and tyrosol were the less potent evaluated com-
pounds with range of MICs at 24 h of 0.12-8% and 0.5-8%
respectively being farnesol more active against C. glabrata
(MIC50 = 0.25%) and C. dubliniensis (MIC = 0.25%).
MFC90 values of the 10 tested compounds and fluco-
nazole are also summarized in Table 2. Those com-
pounds with more fungicidal activity against C. albicans
were geraniol, carvacrol, eugenol, linalool and terpinen-
4-ol whose MFC90 ranged between 0.25 to 0.5%.
Discussion
Essential oils are very complex natural mixtures
extracted from several aromatic plants which can
Table 1 In vitro antifungal activity of the ten natural compounds against reference strains at 24 h (%, v/v)
MIC/MFC
Carvacrol Eugenol Farnesol Geraniol Linalool Menthol Menthone Terpinen-4-ol a-terpineol Tyrosol
Candida albicans ATCC 90028 0.25/0.5 0.12/0.12 8/8 0.12/0.12 0.12/0.12 0.25/0.5 0.25/0.5 0.12/0.12 0.25/0.5 4/8
Candida albicans NCPF 3153 0.25/0.5 0.06/0.12 8/8 0.06/0.12 0.06/0.25 0.25/0.5 0.25/0.5 0.06/0.12 0.12/0.25 8/8
Candida albicans Ca2 0.25/0.5 0.03/0.12 1/8 0.06/0.12 0.06/0.12 0.12/0.5 0.12/0.5 0.06/0.12 0.12/0.25 4/8
Candida glabrata ATCC 90030 0.12/0.5 0.03/0.12 0.12/2 0.12/0.12 0.06/0.06 0.12/0.5 0.12/0.5 0.12/0.12 0.12/0.5 8/8
Candida glabrata NCPF 3203 0.25/0.25 0.03/0.12 0.12/0.5 0.06/0.12 0.12/0.25 0.25/0.5 0.25/0.5 0.06/0.12 0.12/0.5 8/8
Candida dubliniensis NCPF 3949 0.25/0.5 0.06/0.12 0.06/8 0.06/0.12 0.03/0.12 0.12/0.25 0.12/0.25 0.12/0.5 0.12/0.25 4/8
Candida guilliermondii
NCPF3099
0.12/0.5 0.03/0.06 0.12/8 0.06/0.06 0.06/0.06 0.12/0.25 0.12/0.25 0.06/0.12 0.12/0.25 4/8
Candida krusei ATCC 6258 0.12/0.5 0.12/0.5 4/8 0.12/0.5 0.12/1 0.5/2 0.5/2 0.06/0.25 0.12/0.5 2/4
Candida parapsilosis ATCC
22019
0.06/0.5 0.06/0.12 8/8 0.06/0.25 0.06/0.5 0.06/0.25 0.06/0.25 0.06/0.12 0.06/0.5 1/2
Candida tropicalis NCPF3111 0.25/0.5 0.12/0.12 0.5/8 0.06/0.12 0.06/0.12 0.12/0.5 0.12/0.5 0.12/0.12 0.5/0.5 8/8
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Carvacrol MIC range 0.12-0.5 0.12-0.25 0.06-0.25 0.25 0.03 0.12 0.12 0.03-0.5
MIC50/MIC90 0.25/0.5 0.12/0.25 0.12/0.25 0.25/- -/- -/- -/- 0.25/0.25
GM MIC 0.286 0.173 0.151 0.250 0.03 0.12 0.12 0.187
MFC90 0.5 1 1 - - - - 1
Eugenol MIC range 0.06-0.25 0.03-0.25 0.06-0.12 0.06-0.25 0.06 0.06 0.12 0.03-0.25
MIC50/MIC90 0.12/0.25 0.06/0.25 0.06/0.12 0.06/- -/- -/- -/- 0.06/0.25
GM MIC 0.122 0.080 0.079 0.106 0.06 0.06 0.12 0.092
MFC90 0.5 0.25 0.25 - - - - 0.5
Farnesol MIC range 8 0.12-0.5 0.5-8 0.25-8 4 0.25 8 0.12-8
MIC50/MIC90 8/8 0.25/0.5 8/8 8/- -/- -/- -/- 8/8
GM MIC 8 0.267 6.063 4 4 0.25 8 2.487
MFC90 >8 >8 >8 - - - - 8
Geraniol MIC range 0.06-0.12 0.03-0.12 0.03-0.06 0.06-0.12 0.03 0.06 0.12 0.03-0.12
MIC50/MIC90 0.12/0.12 0.06/0.12 0.03/0.06 0.06/- -/- -/- -/- 0.06/0.12
GM MIC 0.097 0.060 0.042 0.079 0.03 0.06 0.12 0.065
MFC90 0.25 0.25 0.25 - - - - 0.25
Linalool MIC range 0.03-0.25 0.03-0.12 0.06-0.25 0.06-0.12 0.03 0.06 0.06 0.03-0.25
MIC50/MIC90 0.12/0.25 0.06/0.12 0.06/0.25 0.06/- -/- -/- -/- 0.06/0.25
GM MIC 0.141 0.064 0.086 0.079 0.03 0.06 0.06 0.085
MFC90 0.5 0.5 0.25 - - - - 0.5
Menthol MIC range 0.25-0.5 0.12-0.5 0.06-0.12 0.12-0.25 0.06 0.12 0.12 0.06-0.5
MIC50/MIC90 0.25/0.5 0.12/0.5 0.12/0.12 0.12/- -/- -/- -/- 0.12/0.25
GM MIC 0.287 0.185 0.112 0.161 0.06 0.12 0.12 0.170
MFC90 111 - - -- 1
Menthone MIC range 0.12-4 0.06-2 0.06-1 0.25-1 0.06 0.25 1 0.06-4
MIC50/MIC90 0.25/2 0.12/0.5 0.06/0.5 0.25/- -/- -/- -/- 0.25/1
GM MIC 0.534 0.229 0.113 0.435 0.06 0.25 1 0.260
MFC90 848 - - -- 8
Terpinen-4-
ol
MIC range 0.06-0.5 0.06-0.12 0.06-0.12 0.06-0.25 0.06 0.12 0.12 0.06-0.5
MIC50/MIC90 0.12/0.5 0.12/0.12 0.06/0.06 0.12/- -/- -/- -/- 0.12/0.5
GM MIC 0.213 0.097 0.064 0.140 0.06 0.12 0.12 0.112
MFC90 0.5 0.5 0.5 - - - - 0.5
a-terpineol MIC range 0.12-0.5 0.12-0.25 0.06-0.25 0.12-0.5 0.06 0.12 0.06 0.06-0.5
MIC50/MIC90 0.25/0.5 0.25/0.25 0.25/0.25 0.25/- -/- -/- -/- 0.25/0.5
GM MIC 0.307 0.186 0.201 0.248 0.06 0.12 0.06 0.210
MFC90 111 - - -- 1
Tyrosol MIC range 1-8 0.5-8 0.5-8 1-8 1 4 1 0.5-8
MIC50/MIC90 1/8 4/8 4/8 8/- -/- -/- -/- 4/8
GM MIC 2.462 3.249 3.482 3.482 1 4 1 2.934
MFC90 8> 8 > 8 - - - - 8
Fluconazole* MIC range 0.25-0.5 0.5-32 0.25-2 2-16 1 0.12 64 0.25-32
MIC50/MIC90 0.5/0.5 8/16 1/2 2/- -/- -/- -/- 1/16
GM MIC 0.435 6.063 0.812 4.595 1 0.12 64 1.576
MFC90 --- - - -- -
* Fluconazole concentrations are in μg/ml
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concentrations. The components are characterized by
low molecular weight and include two groups of distinct
biosynthetic origin. The main group is composed of ter-
penes and terpenoids. The second group includes aro-
matic and aliphatic products [8,9]. Terpenes are made
from combinations of several 5-carbon-base units called
isoprene. The monoterpenes are formed from the cou-
pling of two isoprene units. They are the most represen-
tative molecules constituting 90% of the essential oils
and allow a great variety of structures. Among the
monoterpenes, geraniol and linalool are acyclic alcohols;
menthol, terpinen-4-ol and μ-terpineol monocyclic alco-
hols; menthones are monocyclic ketones; and carvacrol
and thymol are phenols. The sesquiterpenes are formed
from the assembly of three isoprene units, being the far-
nesol an alcohol [8]. The aromatic compounds such the
eugenol, derived from phenylpropane, occur less fre-
quently than the terpenes. Tyrosol is an antioxidant
derivative of phenethyl alcohol present in a variety of
natural sources such as the olive oil.
Many diverse activities of essential oils and their com-
ponents have been shown such as antibacterial, antifun-
gal, antioxidant, antitumor, analgesic and antioxidant
activities [14]. Their antifungal properties are related to
terpenes ability to pass through the fungal cell wall and
locate between fatty acid chains of lipid bilayers, dis-
rupting lipid packaging and altering the structure of the
cell membrane [15,16]. Braga and Del Sasso [15]
demonstrated by scanning electron microscopy that thy-
mol affected the envelope of planktonic C. albicans.
Changes in permeability and in membrane fluidity cause
degradation of cell wall, a decrease in adherence to
host’s surfaces and variable effects such as disruption of
cytoplasm membrane, leakage of cell contents, coagula-
tion of cytoplasm and cell lyses [8,9,14,17].
Compounds, such as carvacrol and geraniol, contain-
ing oxygen are frequently considered as those major
responsible for this effect [8]. In some compounds, such
as carvacrol and thymol, the mechanisms of action seem
to be related to the inhibition of ergosterol biosynthesis
[18].
When evaluating the antimicrobial properties of oils
or their components, the method for determining MIC
is important, in order to permit comparison of the data
generated by different laboratories. For this reason, CLSI
reference method for antifungal susceptibility testing
was used in the current study [12], fluconazole was con-
sidered as comparator and the potential antifungal activ-
ity of almost all the tested components of the essential
oils was observed. Eight of ten natural products: carva-
crol, eugenol, geraniol, linalool, menthol, menthone, ter-
pinen-4-ol, and a-terpineol showed MICs ranged
between 0.03% and 4%. Conversely, farnesol and tyrosol
showed lower antifungal activities with MICs ranging
between 0.12% and ≥ 8%. These latter compounds have
been recognized as quorum-sensing molecules involved
in the coordination of activities among groups of many
single-celled organisms [19,20]. Farnesol and tyrosol are
produced by C. albicans which block and accelerate,
respectively, the morphological transition from yeasts to
hyphae, and are important molecules in different steps
of biofilm development and dispersion to other candidal
foci during colonization and infection [19,20]. Their
weak antifungal activities have been previously described
by several authors [11,16]. However, He et al. [21] and
Dalleau et al. [11] observed the high efficiency of some
terpenes, such as carvacrol, eugenol geraniol and thy-
mol, against C. albicans planktonic and sessile (biofilm)
cells.
The phenylpropanoid eugenol and the oxygenated
monoterpenes geraniol, linalool and terpinen-4-ol were
the compounds with the strongest antifungal activity
against C. albicans. Other authors have observed the
potent antifungal or even fungicidal effects of a-terpi-
neol and terpinen-4-ol [17,22,23].
Carvacrol is an important component of several essen-
tial oils from plants, such as Origanum spp., Satureja
hortensis, Thymus spp. and Thymbra capitata.I na g r e e -
ment with our observations, other authors have found
that this compound exhibited a potent anti-Candida
activity [11,24] even against fluconazole-resistant Can-
dida isolates. In the current study, carvacrol and the
rest of tested compounds, with the exception of farnesol,
menthone and tyrosol, showed important in vitro activ-
ities at very low concentrations against the fluconazole-
resistant C. krusei and the susceptible-dose dependent
C. glabrata isolates. Moreover, carvacrol was able to
inhibit in vitro germ tube formation and filamentation
of C. albicans [8]. Tampieri et al. [16] considered that
carvacrol and geraniol were the most active against C.
albicans as a concentration of 100 ppm of these com-
pounds inhibited the growth of the unique strain tested.
Some studies have shown that primary monoterpenic
alcohols (geraniol and citronellol) have more potent
antifungal activity than tertiary alcohols (linalool). Lina-
lool activity is controversial as some authors consider
this compound inactive while others found a moderate
antifungal activity [8,16]. However, in the current study,
we have observed a strong fungicidal activity in both
geraniol as linalool (MFC90 0.25% for geraniol and 0.5%
for linalool).
Mondello et al. (2006) reported that terpinen-4-ol
(main component of Melaleuca alternifolia -tea tree-oil)
was fungistatic (MIC90 of 0.06%) and fungicidal (MFC90
of 0.125%) against fluconazole-susceptible and resistant
C. albicans isolates. These authors suggested that this
compound could be the mediator of the in vivo activity
Marcos-Arias et al. BMC Complementary and Alternative Medicine 2011, 11:119
http://www.biomedcentral.com/1472-6882/11/119
Page 5 of 7of tea tree oil in a rat model of vulvovaginal candidiasis.
Similar antifungal activities of terpinen-4-ol has been
observed in the present study, and MIC ranged from
0.06-0.12% for C. parapsilosis and C. tropicalis,t o0 . 0 6 -
0.5% for C. albicans. Finally, the phenylpropanoid euge-
nol, main component of cinnamon and clove oils, as in
our study, is considered to have a potent anti-Candida
activity [8,25]. We should stress that there are important
difficulties to compare the current results with those
reported by other authors due to the different in vitro
susceptibility tests used and the potential variation of
susceptibilities among the isolates and strains studied.
Moreover, many studies have tested C. albicans or a
very limited number of fungal species or even a unique
isolate of each species [16,26,27].
On the other hand, the topical use of these naturally
occurring plant active principles is relatively safe, and
their side effects reported in the literature are minor,
self-limiting and occasional [14,24,28,29]. Terpenes have
the potential to be toxic if ingested at higher doses and
can also cause skin irritation at higher concentrations.
However, low doses of carvacrol or terpinen-4-ol did
not induced toxicity for the mucosa in rat models of
Candida vaginitis [24,28]. Moreover, a big advantage of
essential oils and their components is the fact that they
are usually devoid of long-term genotoxic risks [14,29].
Conclusions
Some natural compounds from essential oils, such as
carvacrol, eugenol, geraniol, linalool and terpinen-4-ol
were active in vitro against a collection of oral Candida
isolates. Their fungistatic and fungicidal activities might
convert them into promising alternatives for the topic
treatment of oral candidiasis and Candida-associated
denture stomatitis. However, potential intolerance and/
or toxic effects of some of these compounds should be
taken into consideration.
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